Licence of Right

The products already on the market on 1 September 1971, the date for implementation of the Medicines Act, were given the Product Licences of Right (PLR) that were subject to a review process at a later date. This proposal for review of PLRs is reminiscent of the FDA contract with the National Academy of Sciences/National Research Council (NAS/NRC) in 1966, to evaluate the effectiveness of some 4000 different drug formulations approved on the basis of safety alone between 1938 and 1962 - the year of the Kefauver-Harris Amendment. 

The following minimum standard particulars are required to appear in an advertisement, differentiating between the Public, and Persons Qualified to Prescribe or Supply (PQPS). The particulars are not required on promotional aids which do not incorporate promotional claims and featuring no more than the product name, trademark protection, and company name. All particulars must be compatible with the product s Summary of Product Characteristics. Special particulars apply to registered Homoeopathic medicinal products, and to medicines subject of Product Licences of Right. 

At the start of product licensing in the United Kingdom in 1971, products already on the market were granted Product Licences of Right (PLRs), which were subject to review. Between 1971 and 1982,22 376 lapsed or were revoked or suspended, and 598 had been converted to full product licenses. The Committee of Review of Medicines was deemed to have completed its work in 1991 and was disestablished on 31 March 1992. 

Six certification centres are functioning in Ukraine at present in Kiev, Khar kov, Dmepropetrovsk, Zaporozhje, L vov and Ivano-Frankovsk The best known of them is the NDT Certification Centre at the E O.Paton Electric Welding Institute, which was the first one to receive, already in 1990, the licence of the USSR National Certification Committee for certification of the NDT experts. These certification centres have the right to grant levels I and II (according to EN 473), while level III can only be granted by the National Certification Committee. 

Continuous payment of the patenting expenses by the company will ensure that the industrial partner of such an agreement does not lose interest in the project but nevertheless keeps the patent. As an alternative joint ownership of the patent can be negotiated. Provisions may be included in an agreement to the effect that the licence of the patent shall be terminated if the company does not wish to exercise these rights or does not exert serious efforts to develop or market the invention. 

Jonathan Clayden, Nick Greeves, and Stuart Warren 2012 The moral rights of the authors have been asserted Crown Copyright material reproduced with the permission of the Controller, HMSO (under the terms of the Click Use licence.) Database right Oxford University Press (maker)... 

DuPont had been granted rights to grant non-exclusive sub-licences of the ICI Patents. Union Carbide approached DuPont in October 1942 for a sub-licence, whilst simultaneously contracting to supply the Navy with PE, building a 500-ton PE plant, and then improving the process and product. By the end of the war. Union Carbide had increased their capacity to six times that of DuPont, who were now making 750 tons per annum. Applications were found in extmded film, coated paper, wire and cable insulation, bottles, and pipes. 

---